Login to My NLA Account

News Stories

Mar, 2021

 

Be sure to make plans to join us in June (VIRTUALLY) and September (IN-PERSON) for our premier educational events in 2021:

Summer of Lipids: A Virtual Education Experience with the NLA · June 4-6, 2021

0
No votes yet
Name: NLA News
Feb, 2021

Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved EvkeezaTM (evinacumab-dgnb) as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat adult and pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH). Evkeeza is the first FDA-approved treatment that binds to and blocks the function of angiopoietin-like 3 (ANGPTL3), a protein that plays a key role in lipid metabolism.

0
No votes yet
Name: NLA News
Jan, 2021

The window for nominations to NLA and Chapter leadership positions is now open through February 28, 2021. Open positions include: 

National Lipid Association positions include:

  • At-Large Board Member (up to 7)

Chapter positions include:

  • President-Elect
  • Treasurer
  • Secretary
  • At-Large Board Member (up to 5)

For more information and to nominate your colleagues, visit www.lipid.org/nominate.

0
No votes yet
Name: Top Stories